AMYOTROPHIC LATERAL SCLEROSIS research hub
25 indexed studies · 13 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)
This clinical trial is testing whether a medicine called colchicine can help slow down amyotrophic lateral sclerosis (ALS), a form of motor neurone disease. Adult participants will take either colchicine or a dummy tablet each day for 30 weeks, followed by 36 weeks where everyone receives the trial medicine.
Italy - authorisedHuman Pharmacology (Phase I)- Other
A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA
This study looks at the long-term safety of an experimental medicine called LY4256984 for adults with amyotrophic lateral sclerosis (ALS), commonly known as motor neurone disease. It is an extension study for people who finished an earlier trial, giving the medicine directly into fluid around the spinal cord.
Netherlands · Belgium · Germany - recruitingTherapeutic confirmatory (Phase III)
RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN AMYOTROPHIC LATERAL SCLEROSIS - LIGHTHOUSE II
This study is looking at a medicine called Triumeq for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease. Researchers want to see if Triumeq can help people live longer and improve their daily lives. We are comparing it to a dummy pill to see how well it works.
Sweden · Netherlands · Spain - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)
This study is testing a new medicine, PTC857, for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if it helps improve daily activities and how safe it is compared to a dummy medicine.
Germany · Italy · Norway - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment
This study is testing a new medicine called VRG50635 for people with Amyotrophic Lateral Sclerosis (ALS). It's an early-stage study to see how the medicine works, how much to give, and if it's safe. Both common and inherited forms of ALS are included.
Finland · Belgium · Netherlands - recruitingPHASE1, PHASE2
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
This study is testing a new medicine called VTx-002 for people with Motor Neurone Disease (ALS). It aims to see if it's safe and how well people can cope with it. Researchers will also look at how it affects the disease over five years.
United States · Belgium · Netherlands - recruitingPHASE1, PHASE2
FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
This study is testing a new medicine called TRCN-1023 for people with Amyotrophic Lateral Sclerosis (ALS). It aims to see if the medicine is safe, how the body uses it, and if it could help slow down the disease. The medicine is given as a single injection near the spine.
Germany · Netherlands · United Kingdom - recruitingPHASE3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
This study is testing a drug called pridopidine for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if pridopidine can slow down how ALS progresses and if it's safe to use. Participants will take the drug or a dummy pill daily.
United States · Belgium · Canada - authorisedPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2 Investigation Of Novel Experimental Regimen in Amyotrophic Lateral Sclerosis (PIONEER-ALS): An Open-Label, Uncontrolled, Multicenter Study to Assess the Safety and Tolerability of Two Doses of VTx-002.
This study is testing a new experimental treatment for Motor Neurone Disease (ALS) called VTx-002. It's an early-stage trial (Phase 1/2) focused on checking if the treatment is safe and what side effects it might have. Researchers also want to see if it shows any early signs of helping people.
Netherlands · Belgium · Spain - recruitingPHASE3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
This study is testing a new medicine, Masitinib, for people with Motor Neurone Disease (ALS). It aims to see if Masitinib, when taken with the usual medicine Riluzole, can help slow down the disease compared to taking Riluzole with a dummy pill.
United States · Belgium · Denmark - enrolling by invitation
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
This study aims to understand serious conditions like ALS and similar diseases better. By looking at genes, symptoms, and biological markers, researchers hope to find new ways to develop treatments. People with these conditions and their families are invited to take part.
United States · Germany · South Africa - active not recruitingPHASE1
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
This study is looking at a new medicine called QRL-201 for people with Amyotrophic Lateral Sclerosis (ALS). Researchers want to see if it's safe and how well people tolerate different doses. It's an early-stage study to understand the medicine better.
Belgium · Canada · Germany - recruitingNA
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
This study looks at why people with Amyotrophic Lateral Sclerosis (ALS) lose weight. Researchers will collect blood samples and ask questions to understand this better. They hope to find ways to help people with ALS keep their weight stable, which could improve their health and quality of life.
France - active not recruitingPHASE1
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS
This study is looking at a new medicine called prosetin for people with a condition called Amyotrophic Lateral Sclerosis (ALS). Researchers are checking if prosetin is safe and how it works in the body. They are also comparing it to a dummy medicine (placebo).
United States · Canada · Netherlands - recruiting
Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis
This study looks at a new device called SleepImage to see how well it can spot breathing problems in people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neuron Disease (MND). The goal is to find the best way to know when someone might need help with their breathing, like a special machine called a ventilator.
United Kingdom - active not recruitingPHASE3
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
This study is testing a new medicine called AMX0035 for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if it's safe and can help slow down the disease over 48 weeks compared to a dummy medicine.
United States · Belgium · France - recruitingPHASE1
Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)
This study looks into a new way to deliver medicine for ALS. It uses a special helmet with sound waves to help a drug called IVIG reach the brain better. The main aim is to see if it's safe to do this.
Canada - active not recruitingPHASE2
A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
This study looked at a new medicine called ARGX-119 for adults with Amyotrophic Lateral Sclerosis (ALS) to see if it was safe and helped with muscle function. The study stopped early, not because of safety worries, but because it was unlikely to show a clear benefit.
Belgium · Canada · Denmark - recruiting
Contribution of Diaphragmatic Ultrasound for Monitoring Diaphragmatic Function in Patients With Amyotrophic Lateral Sclerosis
This study looks at how a special type of ultrasound scan of the diaphragm (the main breathing muscle) can help people with Amyotrophic Lateral Sclerosis (ALS). Researchers want to see if this scan can show early signs of breathing problems and help doctors decide the best time to start breathing support.
France - recruiting
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
This study looks at special immune cells called macrophages in people with motor problems, especially ALS. Researchers want to understand if these cells play a part in the disease by comparing them in people with ALS, those with other motor conditions, and healthy individuals, hoping to find new ways to treat ALS.
France - authorisedPhase I and Phase II (Integrated)- Other
Therapeutic approach of repeated transient blood-brain barrier opening in amyotrophic lateral sclerosis
This study is looking at a new way to treat motor neurone disease (ALS). It uses sound waves to briefly open the brain's protective barrier, hoping to let medicines work better. Researchers want to see if this method is safe and if it could help patients.
France - active not recruitingPHASE2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
This study is looking at a new medication, dazucorilant, for people with Amyotrophic Lateral Sclerosis (ALS). Researchers want to see if it's safe and helps improve symptoms. It involves different doses and aims to understand how the drug works and how well it's tolerated by patients.
United States · Belgium · Canada - authorisedHuman Pharmacology (Phase I)- Other
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
This study is testing a new medicine, TQS-168, for people with Motor Neurone Disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS). It's an early-stage trial to see if the medicine is safe, how well the body handles it, and if it shows any signs of helping the condition.
Latvia - authorised (with conditions)Therapeutic confirmatory (Phase III)
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new drug called masitinib for people with Motor Neurone Disease (ALS). It compares masitinib with a dummy pill (placebo) alongside standard treatment to see if it's safe and helps slow down the disease.
Spain · Slovenia · Greece - active not recruitingPHASE3
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
This study, called FUSION, is looking at a new medicine called ION363 for people with a specific type of Motor Neurone Disease (MND) called FUS-ALS. It aims to see if ION363 can help with symptoms and survival for those with a particular gene change.
United States · Belgium · Brazil